vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and SuperCom Ltd (SPCB). Click either name above to swap in a different company.
Beta Bionics, Inc. is the larger business by last-quarter revenue ($27.6M vs $14.2M, roughly 1.9× SuperCom Ltd). SuperCom Ltd runs the higher net margin — 37.5% vs -79.3%, a 116.8% gap on every dollar of revenue. On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs -1.5%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.
BBNX vs SPCB — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $14.2M |
| Net Profit | $-21.9M | $5.3M |
| Gross Margin | 59.5% | 61.2% |
| Operating Margin | -47.4% | 16.3% |
| Net Margin | -79.3% | 37.5% |
| Revenue YoY | 56.6% | -1.5% |
| Net Profit YoY | 23.6% | 79.5% |
| EPS (diluted) | $-0.49 | $1.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | — | ||
| Q3 25 | $27.3M | — | ||
| Q2 25 | $23.2M | $14.2M | ||
| Q1 25 | $17.6M | — | ||
| Q2 24 | — | $14.4M | ||
| Q2 23 | — | $14.1M | ||
| Q2 22 | — | $6.3M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-14.2M | — | ||
| Q2 25 | $-16.9M | $5.3M | ||
| Q1 25 | $-28.7M | — | ||
| Q2 24 | — | $3.0M | ||
| Q2 23 | — | $-2.6M | ||
| Q2 22 | — | $-5.2M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | — | ||
| Q3 25 | 55.5% | — | ||
| Q2 25 | 53.8% | 61.2% | ||
| Q1 25 | 50.9% | — | ||
| Q2 24 | — | 52.3% | ||
| Q2 23 | — | 27.2% | ||
| Q2 22 | — | 41.8% |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | — | ||
| Q3 25 | -62.5% | — | ||
| Q2 25 | -85.5% | 16.3% | ||
| Q1 25 | -105.7% | — | ||
| Q2 24 | — | 7.7% | ||
| Q2 23 | — | -12.2% | ||
| Q2 22 | — | -49.9% |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | — | ||
| Q3 25 | -52.1% | — | ||
| Q2 25 | -72.6% | 37.5% | ||
| Q1 25 | -162.5% | — | ||
| Q2 24 | — | 20.6% | ||
| Q2 23 | — | -18.3% | ||
| Q2 22 | — | -82.4% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.33 | — | ||
| Q2 25 | $-0.39 | $1.32 | ||
| Q1 25 | $-0.93 | — | ||
| Q2 24 | — | $1.19 | ||
| Q2 23 | — | $-10.66 | ||
| Q2 22 | — | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $15.0M |
| Total DebtLower is stronger | — | $23.6M |
| Stockholders' EquityBook value | $271.2M | $37.3M |
| Total Assets | $304.4M | $65.5M |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | — | ||
| Q3 25 | $228.7M | — | ||
| Q2 25 | $249.7M | $15.0M | ||
| Q1 25 | $231.5M | — | ||
| Q2 24 | — | $5.7M | ||
| Q2 23 | — | $1.1M | ||
| Q2 22 | — | $2.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $23.6M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | $29.2M | ||
| Q2 23 | — | $32.9M | ||
| Q2 22 | — | $32.3M |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | — | ||
| Q3 25 | $294.8M | — | ||
| Q2 25 | $301.6M | $37.3M | ||
| Q1 25 | $313.8M | — | ||
| Q2 24 | — | $13.8M | ||
| Q2 23 | — | $3.5M | ||
| Q2 22 | — | $3.7M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | — | ||
| Q3 25 | $330.0M | — | ||
| Q2 25 | $330.0M | $65.5M | ||
| Q1 25 | $338.0M | — | ||
| Q2 24 | — | $49.6M | ||
| Q2 23 | — | $40.8M | ||
| Q2 22 | — | $42.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 2.11× | ||
| Q2 23 | — | 9.49× | ||
| Q2 22 | — | 8.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-2.2M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -25.3% |
| Capex IntensityCapex / Revenue | — | 10.0% |
| Cash ConversionOCF / Net Profit | — | -0.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $-8.7M | — | ||
| Q2 25 | $-13.6M | $-2.2M | ||
| Q1 25 | $-20.0M | — | ||
| Q2 24 | — | $-950.0K | ||
| Q2 23 | — | $-3.4M | ||
| Q2 22 | — | $-4.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | — | ||
| Q3 25 | $-10.0M | — | ||
| Q2 25 | $-15.4M | $-3.6M | ||
| Q1 25 | $-20.3M | — | ||
| Q2 24 | — | $-1.6M | ||
| Q2 23 | — | $-4.5M | ||
| Q2 22 | — | $-4.4M |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | — | ||
| Q3 25 | -36.7% | — | ||
| Q2 25 | -66.2% | -25.3% | ||
| Q1 25 | -115.1% | — | ||
| Q2 24 | — | -10.8% | ||
| Q2 23 | — | -31.5% | ||
| Q2 22 | — | -70.4% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 7.7% | 10.0% | ||
| Q1 25 | 1.9% | — | ||
| Q2 24 | — | 4.2% | ||
| Q2 23 | — | 7.4% | ||
| Q2 22 | — | 4.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.41× | ||
| Q1 25 | — | — | ||
| Q2 24 | — | -0.32× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
